Tuesday, April 29, 2014

Indi Finds $47.25M For Molecular Diagnostics Efforts

Seattle-based Indi, a developer of molecular diagnostics technology, said today that it has raised a total of $47.25M in a combination of equity and debt. The funding included $30.25M in a Series B equity fnding, and $17M in debt financing. The equity investment was led by Baird Capital, and also included InterWest Partners and Wellcome Trust. The debt financing came from Life Sciences Alternative Funding LLC (LSAF). Indi's first product is a molecular diagnostic blood test to address lung cancer. Indi is led by Albert A. Luderer, Ph.D. More information »